Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 32 systematic review(s)/meta-analysis(es). ^[1-31]
• Psoriatic Arthritis (PA): Certolizumab pegol (CZP) demonstrated moderate effectiveness in PA, including achieving American College of Rheumatology 50 (ACR 50) and Psoriatic Arthritis Response Criteria (PsARC) improvements at six months, though it was less effective compared to Secukinumab and Adalimumab in these outcomes. Additionally, CZP prevented radiographic progression but was outperformed by other biologics like Adalimumab, Infliximab, and Etanercept.
• Rheumatoid Arthritis (RA): CZP was significantly effective in achieving low disease activity or remission within three months in RA patients, with an odds ratio of 6.31 compared to placebo, showing substantial effectiveness in this population.
• Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): In nr-AxSpA, CZP provided superior responses on Assessment of SpondyloArthritis International Society (ASAS) criteria (ASAS20/40) and achieved better inactive disease scores (ASDAS) compared to other biologics, indicating its relative effectiveness in this subgroup.
• Crohn's Disease (CD): For CD, CZP showed significant benefits in maintaining clinical remission and response at week 26 compared to placebo, positioning it as an effective maintenance therapy in this condition.
• Psoriatic Arthritis and Rheumatoid Arthritis: CZP showed an increased risk of infections compared to placebo and some other TNF inhibitors, although rates of serious adverse events (SAEs) were not significantly different from placebo in psoriatic arthritis and were comparable to other TNF inhibitors in rheumatoid arthritis.
• Non-Radiographic Axial Spondyloarthritis: In this population, CZP demonstrated a safety profile similar to other biologics, with a generally comparable rate of adverse events despite achieving higher efficacy in some outcomes.
• Crohn's Disease and Psoriasis: CZP did not show a significant difference in serious adverse events compared to placebo in Crohn's disease, and in psoriasis, long-term exposure revealed no new safety signals, with lower SAE rates compared to placebo.